SIR: Alzheimer’s disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of daily living activities, and a variety of neuropsychiatric symptoms and behavioral disturbances.
Increasing evidence shows that neurotoxicity is mediated by CNS inflammatory processes, which involve activation of the microglia by the amyloid-beta, leading to the release of proinflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). Neurotoxic processes mediated by these cytokines may include direct neuronal death by enhancement of apoptosis, decreased synaptic function, and inhibition of hippocampal neurogenesis.
1
Rosiglitazone is used in some studies for improving the symptoms of Alzheimer’s disease but there is controversy about its mechanism of action.
2
There is evidence that shows the effect of rosiglitazone in reducing IL-6.
3 Although a study has shown that rosiglitazone cannot reduce IL-6,
4 it seems that this study was not maintained long enough to determine this effect.
In addition, a study showed that poor sleep is associated with higher interleukin-6 in older caregivers of people with Alzheimer’s disease.
5
According to aforementioned studies, we hypothesize that one of the mechanisms of action of rosiglitazone in ameliorating Alzheimer’s disease is reducing IL-6. Moreover, it seems that this drug can improve the sleep of people with Alzheimer’s disease.
Prescribing other IL-6 reducers as clenbuterol may be a good treatment for Alzheimer’s disease. On the other hand, TNF-alpha antagonists, like thalidomide, infliximab, etanercept, and adalimumab, may be effective in Alzheimer’s disease.
Surely, clinical trials are needed to validate our hypothesis.